Biomarker analysis to support oncology clinical trials

Explicyte Immuno-Oncology > CRO Services > Translational > Biomarker analysis to support oncology clinical trials

Supporting translational research in oncology for over a decade

Over the past decade, Explicyte has partnered with pharmaceutical companies and Comprehensive Cancer Centers to advance translational immuno-oncology—contributing to 30+ peer-reviewed publications that characterize resistance mechanisms to cancer immunotherapies and identify predictive biomarkers of anti-tumor immune response.

To support biomarker programs from discovery through clinical development, we have built a dedicated infrastructure for biomarker analysis and clinical trial support, including:

  • Clinical-grade sample management: ISO-certified quality management for end-to-end traceability, standardized tissue processing and QC to control variability, and secure specimen storage with documented return/shipment upon request.

  • Fit-for-purpose experimental strategy: study designs that minimize sample consumption and optimize turnaround time and cost, leveraging highly multiplex technologies to extract maximum information from precious clinical specimens (Explicyte is a 10x Genomics Certified Service Provider).

  • Integrated image, omics & biostatistics: validated workflows to process and analyze high-dimensional datasets, integrate clinical metadata, and deliver clear, decision-ready reports with publication-ready figures and methods/QC documentation.

  • ISO9001 & ISO13485 biomarker assay development services (single- and multiplex IHC/IHF panels) to support patient selection in clinical trials. Our first validated panel under this quality framework is a multiplex panel for TLS detection & scoring.

Tell us about your project
explicyte immuno-oncology bergonie institut cancer centrer cro translational

Explicyte is headquartered at the Institut Bergonié Comprehensive Cancer Center in Bordeaux, France

JAMA Oncology
Nature Cancer
The Lancet Oncology
Journal of clinical oncology
Journal of Hematology & Oncology
Immunity
Nature medicine
Biomarker Research
Clinical Cancer Research

Platforms for tissue and peripheral biomarker analysis in clinical trials

Our technology offer allows us to process both tumor biopsies (Fresh/FFPE) and liquid clinical samples for the discovery of predictive biomarkers or for the monitoring early signals of pharmacodynamic activity in the context of clinical trials.

Let's move your project forward

ISO-certified services for the design, development & analysis of IHC/IHF biomarkers panels for oncology trials

Our ISO-certified histopathology workflow to support clinical trials includes:

  • Assay design: Marker selection, positive, & negative control tissues

  • Panel development: Antibody & staining sequence validation for multiplex panel

  • Method validation: Sensitivity, specificity, reproducibility, inter- & intra-operator reproducibility (including pathology review harmonization)

  • Validation on clinical cohort: Evaluation of assay robustness & clinical relevance

  • IHC/IF assay performance in the context of clinical trials with a compliant assay report, issued with assay documentation package suitable for sponsor filings / study documentation
Let's move your project forward
ISO-certified biomarker services CRO oncology clinical trials

Explicyte is certified ISO 13485:2016 & ISO 9001:2015 by Euro-Quality System (certificates 260133/1637F/1 and 260133/1637F/2). Scope: Precision Oncology – Design and development of novel tissue biomarkers – Tissue biomarker testing services to support therapeutic decision-making

Why working with Explicyte?

Experts
in Immuno-Oncology

  • A comprehensive platform & certified services to generate robust datasets
  • Over 10 years of experience in TME & peripheral marker profiling
  • 30+ peer-reviewed publications in high-impact immuno-oncology journals
See our latest papers

Personalized
approach

  • Scientific interactions to discuss your project needs (e.g. nature of samples, biomarker panels, etc.)
  • A dedicated study director (PhD) from experimental plan to final report discussion
  • On-site data science team for rapid and actionable results
Talk to our team
JAMA Oncology
Nature Cancer
The Lancet Oncology
Journal of clinical oncology
Journal of Hematology & Oncology
Immunity
Nature medicine
Biomarker Research
Clinical Cancer Research
Molecular Cancer

Your contacts

explicyte team 2024

Talk to our team !

Paul Marteau, PharmD (preclinical study director), Imane Nafia, PhD (CSO), Loïc Cerf, MSc (COO), Alban Bessede, PhD (founder, CEO), Jean-Philippe Guégan, PhD (CTO)

Tell us about your project !

    Select department:

    Site map Terms Of Service Privacy Policy  © Explicyte - Immusmol 2023 | All Rights Reserved.
    WordPress Lightbox